Impact Factor
2.87
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.81
272 total citations
h5-index
17
h5 depth signal
Cited share
59.4%
95 of 160
Total citations
272
Citation footprint
Metric signal
1.63
External metric anchor
Self-citation
2.2%
6 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
India
237
United States
48
Italy
47
Iran
38
Tunisia
29
Citing Fields of Research
Pharmacology & Toxicology
159
Allergies
99
Patient Care
66
Medical Ethics
59
Antibiotic & Antibacterial Agents
50
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,120
Articles tracked across the journal lifetime
Indexed publication set
160
95 cited publications
Last 12 months
55
5.0 publications/month
Open access share
3.6%
2 OA publications in the last year
Leading citing country
India
237 citing publications
Leading citing field
Pharmacology & Toxicology
159 citing publications
Latest tracked publication
13 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Jan. 2006-
v1n1, Jan. 2006-
Research Focus & Classification
Indexed Subjects
Allergies
Pharmacology & Toxicology
Diabetes
Antibiotic & Antibacterial Agents
Patient Care
Anesthetic & Pain Medicine
Medical Ethics
Broad Categories
Drug Therapy
Pharmacology
Allergies
Medical Ethics
Antibiotic & Antibacterial Agents
Virology
Anesthetic & Pain Medicine
Substance Abuse
MeSH Descriptors
Drug-Related Side Effects and Adverse Reactions
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.2174/0115748863515024261006073915
Open DOI
Disproportionality Analysis of Reporting Signals for Pericardial Disorders in the FDA Adverse Event Reporting System, 2000 to 2025
Background/Objectives: Pericardial syndromes cause significant morbidity, decreased quality of life, and rarely mortality. Drug-associated pericardial syndromes are underreported. This study characterized reports of pericardial disorders...
02
DOI 10.2174/0115748863527540260928113823
Open DOI
Bilateral Lower Extremity Edema During Donepezil Treatment: A Case Report
Introduction/ Background: Acute bilateral lower-extremity edema is uncommon and often results from medication side effects, acute heart failure, nephrotic syndrome, or bilateral deep vein thrombosis. Drugs such as dihydropyridine calcium...
03
DOI 10.2174/0115748863492031260920211559
Open DOI
Efficacy and Safety of Sequential Combined Immunomodulatory Systemic Therapies Used in the Management of Refractory Cytokine Release Syndrome in Critically Ill Patients with COVID-19
Introduction/Objective: Severe Coronavirus Disease 2019 (COVID-19) is characterized by systemic hyperinflammation and cytokine storm, a series of clinical conditions caused by excessive immune reactions. Although numerous studies have be...
04
DOI 10.2174/0115748863494991260907111941
Open DOI
Duality of Rarity of Chemotherapy-induced Flagellate Erythema among Cancer Patients: A Case Report with 26 Years of Evidence in Oncology
Introduction: Flagellate Dermatitis (FD) due to anticancer therapy is a rare, unusual Adverse Drug Reaction (ADR) in oncology. The current case describes the impact of financial constraints on the choice of anticancer therapy, the occurr...
05
DOI 10.2174/0115748863492008260909072146
Open DOI
Pharmacovigilance Knowledge, Attitudes, and ADR Reporting Behaviour Among Physicians and Pharmacists in a Tertiary Hospital
Introduction: Adverse Drug Reactions (ADRs) remain a major challenge in pharmacovigilance due to persistent underreporting. Healthcare professionals’ knowledge, attitudes, and reporting practices play an important role in effective ADR m...
06
DOI 10.2174/0115748863499430260827111726
Open DOI
Possible Interaction of the Gut-selective Antibiotic Rifaximin with Carvedilol Associated with Transient Indirect Hyperbilirubinemia: A Case Report
Introduction: Rifaximin is a gut-selective antimicrobial with poor bioavailability. One potential indication of rifaximin use is hepatic encephalopathy. The adverse effects are limited to the gastrointestinal system, and systemic disturb...
07
DOI 10.2174/0115748863487416260803065613
Open DOI
Safety of Chronic Proton Pump Inhibitor Therapy: An Updated Systematic Review of Serious Adverse Events
Background: Proton Pump Inhibitors (PPIs) are widely prescribed for acid-related disorders and are generally considered safe for short-term therapy. However, growing evidence has raised concerns regarding Serious Adverse Events (SAEs) as...
08
DOI 10.2174/0115748863451595260605050739
Open DOI
Advancing Pharmacovigilance: AI and Deep Learning Approaches to Detect Adverse Drug Reactions from Big Data
The systematic monitoring of post-marketing drug safety is paramount to ensuring patient welfare and population-level health, requiring the timely detection and prevention of adverse drug events. Traditional pharmacovigilance schemes, wh...
09
DOI 10.2174/0115748863471075260724094945
Open DOI
Enhancing Patient Safety: Patterns of Adverse Drug Reaction Reporting in a Tertiary Care Hospital in Eastern India: A Record-based Retrospective Study
Background: Adverse drug reactions (ADRs) are a significant cause of increased morbidity and mortality, prolonged hospitalisation, and financial burden on patients. Regular ADR monitoring helps formulate strategies for the safe and effec...
10
DOI 10.2174/0115748863490734260714102047
Open DOI
Dapsone-Induced Photosensitivity: A Rare and Overlooked Clinical Dilemma
Introduction: Dapsone (4,4’- diamino diphenyl sulfone, DDS) is an antimicrobial sulfonamide used for non-dermatological and dermatological disorders. Dapsone has been associated with a wide range of cutaneous adverse effects, with photos...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.